These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23404232)

  • 1. Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.
    Ross MI; Wu E; Wilkins JT; Gupta D; Shen S; Aulwes D; Montero K; Holly TA
    J Nucl Cardiol; 2013 Apr; 20(2):197-204. PubMed ID: 23404232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.
    Parker MW; Morales DC; Slim HB; Ahlberg AW; Katten DM; Cyr G; Mathur S; Ardestani A; Barmpouletos D; Iyah GS; Borer SM; Heller GV
    J Nucl Cardiol; 2013 Apr; 20(2):185-96. PubMed ID: 23188626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.
    Thompson RC; Patil H; Thompson EC; Thomas GS; Al-Amoodi M; Kennedy KF; Bybee KA; Iain McGhie A; O'Keefe JH; Oakes L; Bateman TM
    J Nucl Cardiol; 2013 Apr; 20(2):214-21; quiz 222-6. PubMed ID: 23233371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial.
    Ballany W; Mansour K; Morales Demori R; Al-Amoodi M; Doukky R
    J Nucl Cardiol; 2014 Jun; 21(3):496-502. PubMed ID: 24519563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison.
    Cury RC; Kitt TM; Feaheny K; Akin J; George RT
    J Cardiovasc Comput Tomogr; 2014; 8(1):2-12. PubMed ID: 24314823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regadenoson: a focused update.
    Ghimire G; Hage FG; Heo J; Iskandrian AE
    J Nucl Cardiol; 2013 Apr; 20(2):284-8. PubMed ID: 23229649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results.
    Janvier L; Pinaquy J; Douard H; Karcher G; Bordenave L
    J Nucl Cardiol; 2017 Feb; 24(1):34-40. PubMed ID: 26542990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol.
    Thomas GS; Cullom SJ; Kitt TM; Feaheny KM; Ananthasubramaniam K; Gropler RJ; Jain D; Thompson RC
    J Nucl Cardiol; 2017 Jun; 24(3):788-802. PubMed ID: 28224449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.
    Mahmarian JJ; Peterson LE; Xu J; Cerqueira MD; Iskandrian AE; Bateman TM; Thomas GS; Nabi F
    J Nucl Cardiol; 2015 Apr; 22(2):248-61. PubMed ID: 25287737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
    Doukky R; Fughhi I; Campagnoli T; Wassouf M; Ali A
    J Nucl Cardiol; 2017 Feb; 24(1):112-118. PubMed ID: 26582040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
    Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
    J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics.
    Mekkaoui C; Jadbabaie F; Dione DP; Meoli DF; Purushothaman K; Belardinelli L; Sinusas AJ
    JACC Cardiovasc Imaging; 2009 Oct; 2(10):1198-208. PubMed ID: 19833310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
    AlJaroudi WA; Alraies MC; Cerquiera MD; Jaber WA
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):341-8. PubMed ID: 23208701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of left ventricular ejection fraction reserve from early gated regadenoson stress Tc-99m high-efficiency SPECT.
    Brodov Y; Fish M; Rubeaux M; Otaki Y; Gransar H; Lemley M; Gerlach J; Berman D; Germano G; Slomka P
    J Nucl Cardiol; 2016 Dec; 23(6):1251-1261. PubMed ID: 27387521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of regadenoson stress testing in patients with pulmonary hypertension.
    Moles VM; Cascino T; Saleh A; Mikhova K; Lazarus JJ; Ghannam M; Yun HJ; Konerman M; Weinberg RL; Ficaro EP; Corbett JR; McLaughlin VV; Murthy VL
    J Nucl Cardiol; 2018 Jun; 25(3):820-827. PubMed ID: 27896702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of transient ischemic dilation with regadenoson myocardial perfusion imaging.
    Lester D; El-Hajj S; Farag AA; Bhambhvani P; Tauxe L; Heo J; Iskandrian AE; Hage FG
    J Nucl Cardiol; 2016 Oct; 23(5):1147-1155. PubMed ID: 26490267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label, but on-target: use of regadenoson with exercise.
    Hendel RC; Frost L
    J Nucl Cardiol; 2013 Apr; 20(2):179-81. PubMed ID: 23143811
    [No Abstract]   [Full Text] [Related]  

  • 19. ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson.
    Qamruddin S; Huang HW; Mehra A; Bonyadlou S; Yoon AJ
    Clin Nucl Med; 2016 Jan; 41(1):62-4. PubMed ID: 26447370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.
    Iskandrian AE; Bateman TM; Belardinelli L; Blackburn B; Cerqueira MD; Hendel RC; Lieu H; Mahmarian JJ; Olmsted A; Underwood SR; Vitola J; Wang W;
    J Nucl Cardiol; 2007; 14(5):645-58. PubMed ID: 17826318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.